Drug Landscape ›
salmeterol 50mcg ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 10
Most-reported reactions
Anxiety — 1 report (10%) Drug Ineffective — 1 report (10%) Drug Interaction — 1 report (10%) Drug Level Increased — 1 report (10%) Dyspnoea — 1 report (10%) Fall — 1 report (10%) Infection — 1 report (10%) Myopathy — 1 report (10%) Nausea — 1 report (10%) Product Substitution Issue — 1 report (10%)
Source database →
salmeterol 50mcg in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is salmeterol 50mcg approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for salmeterol 50mcg in United States?
GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.